RT Journal
A1 Friedrich MJ
T1 DEbate continues on use of psa testing for early detection of prostate cancer
JF JAMA
JO JAMA
YR 2011
FD June 8
VO 305
IS 22
SP 2273
OP 2276
DO 10.1001/jama.2011.777
UL http://dx.doi.org/10.1001/jama.2011.777
AB 
Prostate cancer appears in a large percentage of men as they age, but is indolent most of the time. Critics emphasize that PSA testing is an imperfect screening tool because it does not differentiate clinically significant tumors from ones that would never cause harm, and the result is overdiagnosis and overtreatment. Others defend the use of PSA testing and say that a more rational, evidence-based approach to using it can help detect and treat prostate cancer early in men who would die of the disease.